In human myeloid malignancies, inactivating mutations of ASXL1 and TET2 often occur together in the same patient's malignant cells (Abdel-Wahab et al., 2012b; Patnaik et al., 2016), suggesting that loss of these two tumor suppressors may act synergistically in myeloid transformation. This evidence concerns the gene ASXL1 and cancer.